Certara (CERT) Stock Forecast & Price Target

$11.69 -0.09 (-0.76%)

As of 05/20/2025 04:00 PM Eastern

Certara - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 8 Analyst Ratings

Sell
0

Hold
3

Buy
5

Based on 8 Wall Street analysts who have issued ratings for Certara in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 8 analysts, 3 have given a hold rating, and 5 have given a buy rating for CERT.

Consensus Price Target

$15.67
34.02% Upside

According to the 8 analysts' twelve-month price targets for Certara, the average price target is $15.67. The highest price target for CERT is $18.00, while the lowest price target for CERT is $13.00. The average price target represents a forecasted upside of 34.02% from the current price of $11.69.

Get the Latest News and Ratings for CERT and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Certara and its competitors.

CERT Analyst Ratings Over Time

Type	Current Forecast 5/21/24 to 5/21/25	1 Month Ago 4/21/24 to 4/21/25	3 Months Ago 2/21/24 to 2/20/25	1 Year Ago 5/22/23 to 5/21/24
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	5 Buy rating(s)	4 Buy rating(s)	2 Buy rating(s)	4 Buy rating(s)
Hold	3 Hold rating(s)	4 Hold rating(s)	6 Hold rating(s)	7 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$15.67	$15.17	$15.92	$20.06
Forecasted Upside	34.02% Upside	4.81% Upside	17.47% Upside	21.59% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Hold	Hold

CERT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

CERT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Certara Stock vs. The Competition

Type	Certara	Medical Companies	S&P 500
Consensus Rating Score	2.63	2.81	2.54
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	34.42% Upside	4,740.06% Upside	12.75% Upside
News Sentiment Rating	Positive News See Recent CERT News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
5/8/2025	Barclays 3 of 5 stars	Luke Sergott Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$11.00 ➝ $14.00	+22.16%
5/6/2025	JMP Securities 2 of 5 stars	Constantine Davides Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
4/16/2025	KeyCorp 3 of 5 stars	Scott Schoenhaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$15.00 ➝ $18.00	+29.68%
4/11/2025	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Joe Vruwink Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Neutral ➝ Neutral	$9.00 ➝ $13.00	+23.69%
2/27/2025	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Market Perform
2/27/2025	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Jeff Garro Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$17.00 ➝ $17.00	+37.21%
2/27/2025	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	B. Smith Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$16.00	+29.76%
9/27/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Leonard Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$16.00 ➝ $16.00	+49.53%
3/1/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Hold ➝ Hold	$14.00 ➝ $15.50	-8.18%
2/26/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Cherny Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
Get the Latest News and Ratings for CERT and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Certara and its competitors with MarketBeat's FREE daily newsletter.
2/26/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Market Perform	$19.00	+12.16%
8/15/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$27.00 ➝ $24.00	+39.62%
8/10/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$27.00 ➝ $21.00	+17.19%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 02:54 AM ET.

Should I Buy Certara Stock? CERT Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, May 5, 2025. Please send any questions or comments about these Certara pros and cons to contact@marketbeat.com.

Certara
Bull Case

Here are some ways that investors could benefit from investing in Certara, Inc.:

Certara, Inc. has received multiple "overweight" ratings from analysts, indicating strong confidence in its growth potential. This suggests that the stock may outperform the market.
The company has a diverse range of innovative software products, including the latest versions of the Simcyp Simulator and Phoenix WinNonlin, which are essential for drug development and regulatory compliance.
As of the latest trading session, the stock price is $12.99, which is below its fifty-two week high of $17.81, indicating potential for price appreciation as the market recognizes its value.
Certara, Inc. operates in the growing field of biosimulation, which is increasingly important in drug discovery and development, positioning the company well for future demand.
The company has a solid financial foundation with a quick ratio of 2.86, indicating good short-term liquidity, and a manageable debt-to-equity ratio of 0.28, suggesting low financial risk.

Certara
Bear Case

Investors should be bearish about investing in Certara, Inc. for these reasons:

The stock has a negative PE ratio of -64.95, which may indicate that the company is currently unprofitable, raising concerns about its ability to generate earnings in the near term.
Despite positive analyst ratings, the average target price of $15.17 suggests limited upside potential from the current price, which may not attract aggressive investors.
Certara, Inc. has a beta of 1.64, indicating higher volatility compared to the market, which could lead to larger price swings and increased risk for investors.
The company has experienced fluctuations in its stock price, with a fifty-day simple moving average of $11.70, which may signal instability in investor confidence.
With four analysts rating the stock as a hold, there may be a lack of strong bullish sentiment, which could limit upward momentum in the stock price.

CERT Forecast - Frequently Asked Questions

: According to the research reports of 8 Wall Street equities research analysts, the average twelve-month stock price forecast for Certara is $15.67, with a high forecast of $18.00 and a low forecast of $13.00.
: 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Certara in the last twelve months. There are currently 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CERT shares.
: According to analysts, Certara's stock has a predicted upside of 34.02% based on their 12-month stock forecasts.
: Over the previous 90 days, Certara's stock had 1 upgrade by analysts.
: Certara has been rated by research analysts at Barclays, JMP Securities, KeyCorp, Robert W. Baird, Stephens, TD Cowen, and William Blair in the past 90 days.
: Analysts like Certara less than other "medical" companies. The consensus rating score for Certara is 2.63 while the average consensus rating score for "medical" companies is 2.81. Learn more on how CERT compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NASDAQ:CERT) was last updated on 5/21/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Certara (CERT) Stock Forecast & Price Target